卡培他滨联合腹腔灌注顺铂及香菇多糖对晚期胃癌合并癌性腹水的疗效观察

Efficacy of capecitabine combined with intraperitoneal injection of cisplatin and lentinan on ascites associated with advanced gastric cancer

目的:评价对晚期胃癌合并癌性腹水患者在采用卡倍他滨联合腹腔灌注顺铂化疗的基础上联用香菇多糖干预的临床效果。方法:选择晚期胃癌合并癌性腹水患者64例,按照随机数表法将其分为行口服卡培他滨联合腹腔灌注顺铂治疗的对照组(n=32)与联合使用香菇多糖治疗的实验组(n=32),对比临床疗效。结果:实验组腹腔积液治疗总有效率高于对照组(P<0.05),胃癌控制率高于对照组(P<0.05),1年后生存率高于对照组(P<0.05)。两组不良反应数据对比无统计学意义(P>0.05)。结论:对晚期胃癌合并癌性腹水患者在采用卡倍他滨联合腹腔灌注顺铂化疗的基础上联用香菇多糖干预效果更为理想,可明显改善患者腹腔积液情况,有助于提高病灶控制率,患者短期生存率高,且不会造成不良反应增加,用药相对安全。

Objective:To investigate the clinical effect of carbobetabine plus intraperitoneal cisplatin chemotherapy combined with lentinan on ascites associated with advanced gastric cancer.Methods:Sixty-two patients with advanced gastric cancer complicated with cancerous ascites were selected and divided into control group and experimental group by random number table method.The control group was treated by oral capecitabine combined with intraperitoneal perfusion with cisplatin,and the experimental group was treated with lentinan on the basis of the control group.The clinical efficacy of the two groups was compared.Results:The total effective rate,gastric cancer control rate and 1-year survival rate of the experimental group were all higher than those of the control group(P<0.05),the differences were statistically significant.There was no statistically significant difference in adverse reactions between the two groups(P>0.05).Conclusion:Lentinan combined with cabotabine combined with intraperitoneal cisplatin chemotherapy has an ideal effect in the treatment of patients with advanced gastric cancer complicated with cancerous ascites,which can significantly improve the patients'peritoneal effusion and contribute to the improvement of lesion control rate.The patients have a high short-term survival rate without increasing adverse reactions,and the drug is relatively safe.